Advertisement

AAPS PharmSciTech

, 20:114 | Cite as

Investigating the Mechanism of l-Valine in Improving the Stability of Gabapentin Combining Chemical Analysis Experiments with Computational Pharmacy

  • Jiaxin WangEmail author
  • Lixiang Yang
  • Daixi Li
  • Ying Xu
  • Li Yang
  • Hong Zhao
  • Zhuangzhi Zhu
  • Hansen LuanEmail author
  • Qiong LuoEmail author
Research Article

Abstract

The mechanism of l-Val on how to improve the stability of gabapentin (GBP) was described by the combination of chemical analysis experiments and computer simulations. Scanning electron microscope (SEM), powder X-ray diffraction (PXRD), and differential scanning calorimeter (DSC), coupled with attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR), were used to identify β-GBP prepared by rapid solvent removal method. The reaction barriers on crystal planes, β-GBP (100) and β-GBP (10-1), are smaller than α-GBP and γ-GBP, reaching 276.65 kJ/mol and 299.57 kJ/mol, respectively. Thus, it was easier for β-GBP to form lactam, and the occurrence of β-GBP would lead the worse stability of α-GBP. The addition of neutral amino acids such as l-Val could improve the stability of α-GBP effectively. The adsorption energy of α-GBP (002) crystal plane with l-Val is larger than that of other crystal planes, reaching 42.17 kJ/mol. Hydrogen bond was the combination of l-Val and GBP main crystal planes, which could inhibit the crystal transformation of α-GBP. These results suggest that neutral amino acid protectants, such as l-Val, could improve the stability of α-GBP effectively, and inhibition of crystal transformation is one of the effective methods to improve the stability of polymorphic drugs.

KEY WORDS

Stability Computational pharmacy Hydrogen bond Reaction barriers Polymorphic drugs Amino acid 

Notes

Funding

This work was supported by Shanghai Science and Technology Commission R&D Platform Special (18DZ2290500).

Compliance with Ethical Standards

Disclaimers

The views expressed in the manuscript entitled “Investigating The Mechanism of L-Valine In Improving The Stability of Gabapentin Combining Chemical Analysis Experiments With Computational Pharmacy,” which we wish to be considered for publication in “AAPS PharmSciTech,” are my own and not an official position of the institution or funder.

References

  1. 1.
    Zong Z, Desai SD, Kaushal AM, Barich DH, Huang H, Munson EJ, et al. The stabilizing effect of moisture on the solid-state degradation of gabapentin. AAPS PharmSciTech. 2011;12(3):924–31.CrossRefGoogle Scholar
  2. 2.
    Herrmann M, Menz J, Olsson O, Kümmerer K. Identification of phototransformation products of the antiepileptic drug gabapentin: biodegradability and initial assessment of toxicity. Water Res. 2015;15(85):11–21.CrossRefGoogle Scholar
  3. 3.
    Kansal S, Sinha P, Agarwa R, Sharma V. Comparison of analgesic efficacy of antiepileptic gabapentin with conventional analgesic diclofenac in rat experimental models. J Drug Deliv Ther. 2017;1(7):44–8.Google Scholar
  4. 4.
    Singh D, Kennedy DH. The use of gabapentin for the treatment of postherpetic neuralgia. Clin Ther. 2003;25(3):852–89.CrossRefGoogle Scholar
  5. 5.
    Hsu CH, Ke WT, Lin SY. Progressive steps of polymorphic transformation of gabapentin polymorphs studied by hot-stage FTIR microspectroscopy. J Pharm Pharm Sci. 2010;13(1):67–77.CrossRefGoogle Scholar
  6. 6.
    Reddy LS, Bethune SJ, Kampf JW, Rodríguez-Hornedo N. Cocrystals and salts of gabapentin: pH dependent cocrystal stability and solubility. Cryst Growth Des. 2009;1(9):378–85.CrossRefGoogle Scholar
  7. 7.
    Taylora CP, Angelottib T, Faumanc E. Pharmacology and mechanism of action of pregabalin: the calcium channel α2–δ (alpha2–delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73(2):137–50.CrossRefGoogle Scholar
  8. 8.
    Delaney SP, Smith TM, Korter TM. Conformation versus cohesion in the relative stabilities of gabapentin polymorphs. Roval Soc Chem. 2014;4:855–64.Google Scholar
  9. 9.
    Braga D, Grepioni F, Maini L, Brescello R, Cotarca L. Simple and quantitative mechanochemical preparation of the first zinc and copper complexes of the neuroleptic drug gabapentin. CrystEngComm. 2008;10(5):469–71.CrossRefGoogle Scholar
  10. 10.
    Reece HA, Levendis DC. Polymorphs of gabapentin. Acta Crystallogr C. 2008;64(3):o105–8.CrossRefGoogle Scholar
  11. 11.
    Lin S, Hsu C, Ke W. Solid-state transformation of different gabapentin polymorphs upon milling and co-milling. Int J Pharmaceut. 2010;396(1–2):83–90.CrossRefGoogle Scholar
  12. 12.
    Tinmanee R, Larsen SC, Morris KR, Kirsch LE. Quantification of gabapentin polymorphs in gabapentin/excipient mixtures using solid state 13 C NMR spectroscopy and X-ray powder diffraction. J Pharmaceut Biomed. 2017;146:29–36.CrossRefGoogle Scholar
  13. 13.
    Tinmanee R, Stamatis SD, Ueyama E, Morris KR, Kirsch LE. Polymorphic and covalent transformations of gabapentin in binary excipient mixtures after milling-induced stress. Pharm Res-Dordr. 2018:35–9.Google Scholar
  14. 14.
    Zong Z, Qiu J, Tinmanee R, Kirsch LE. Kinetic model for solid-state degradation of gabapentin. J Pharm Sci-US. 2012;101(6):2123–33.CrossRefGoogle Scholar
  15. 15.
    Potschka H, Feuerstein TJ, Löscher W. Gabapentin-lactam, a close analogue of the anticonvulsant gabapentin, exerts convulsant activity in amygdala kindled rats. Naunyn Schmiedeberg's Arch Pharmacol. 2000;361(2):200–5.CrossRefGoogle Scholar
  16. 16.
    Jehle T, Feuerstein TJ, Lagrèze WA. The effect of gabapentin and gabapentin-lactam on retinal ganglion cell survival. Situation after acute retinal ischemia in animal models. Europe PMC. 2001;98(3):237–41.Google Scholar
  17. 17.
    Hsu C, Lin S. Rapid examination of the kinetic process of intramolecular lactamization of gabapentin using DSC–FTIR. Thermochim Acta. 2009;486(1–2):5–10.CrossRefGoogle Scholar
  18. 18.
    Zucker B, Ludin DE, Gerds TA, Lücking CH, Landwehrmeyer GB, Feuerstein TJ. Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington's disease. Naunyn Schmiedeberg's Arch Pharmacol. 2004;270(2):131–9.Google Scholar
  19. 19.
    SH Q, invento Stable pharmaceutical preparation of γ-aminobutyric acid derivative and preparation method. 1999 1999-05-10.Google Scholar
  20. 20.
    Chakravarty P, Lubach JW, Hau J, Nagapudi K. A rational approach towards development of amorphous solid dispersions: experimental and computational techniques. Int J Pharmaceut. 2017;519(1–2):44–57.CrossRefGoogle Scholar
  21. 21.
    Zhao Q, Miriyala N, Su Y, Chen W, Gao X, Shao L, et al. Computer-aided formulation design for a highly soluble lutein–cyclodextrin multiple-component delivery system. Mol Pharmaceut. 2018;15(4):1664–73.CrossRefGoogle Scholar
  22. 22.
    Ouyang D, Smith SC. Application of molecular modeling in drug delivery. Computational Pharmaceutics. Hoboken: Wiley; 2015. p. 1–4.Google Scholar
  23. 23.
    Ramezanpour M, Leung SSW, Delgado-Magnero KH, Bashe BYM, Thewalt J, Tieleman DP. Computational and experimental approaches for investigating nanoparticle-based drug delivery systems. Biochim Biophys Acta Biomembr. 2016;1858(7):1688–709.CrossRefGoogle Scholar
  24. 24.
    Ouyang D. Investigating the molecular structures of solid dispersions by the simulated annealing method. Chem Phys Lett. 2012;554:177–84.CrossRefGoogle Scholar
  25. 25.
    Chen W, Ouyang D. Investigation of molecular dissolution mechanism of ketoprofen binary and ternary solid dispersions by molecular dynamics simulations. Mol Simul. 2017;43:1074–80.CrossRefGoogle Scholar
  26. 26.
    Zhang Q, Jiang L, Mei X. Thermodynamic and kinetic investigation of agomelatine polymorph transformation. Pharm Dev Technol. 2016;2(21):196–203.CrossRefGoogle Scholar
  27. 27.
    Frisch M J TGWS. Gaussian 09. Revision D.02. 2009.Google Scholar
  28. 28.
    Li G, Wang D, Huang Z. Crystalline interface phase study. J Synth Cryst. 2001;2(30):171–7.Google Scholar
  29. 29.
    Liu XY, Boek ES, Briels WJ. Prediction of crystal growth morphology based on structural analysis of the solid–fluid interface. Nature. 1995;6520(374):342–5.CrossRefGoogle Scholar
  30. 30.
    Liu N, Zhou C, Shu Y, Wang B, Wang W. Molecular dynamics study on crystal morphology of N-mercaptourea dinitramide salt. Chem J Chin Univ. 2017;(12):2231–7.Google Scholar
  31. 31.
    André V, Fernandes A, Santos PP, Duarte MT. On the track of new multicomponent gabapentin crystal forms: synthon competition and pH stability. Cryst Growth Des. 2011;6(11):2325–34.CrossRefGoogle Scholar
  32. 32.
    Jain D, Mishra M, Rani A. Synthesis and characterization of novel aminopropylated fly ash catalyst and its beneficial application in base catalyzed Knoevenagel condensation reaction. Fuel Process Technol. 2012;95:119–26.CrossRefGoogle Scholar
  33. 33.
    Hamied Y, Kankan R, Rao D, ^inventors; Polymorphic forms of olanzapine. 2002 2002-02-19.Google Scholar
  34. 34.
    Wildfong PLD, Morley NA, Moore MD, Morris KR. Quantitative determination of polymorphic composition in intact compacts by parallel-beam X-ray powder diffractometry II-data correction for analysis of phase transformations as a function of pressure. J Pharmaceut Biomed. 2005;39(1–2):1–7.CrossRefGoogle Scholar
  35. 35.
    Achrai B, Libster D, Aserin A, Garti N. Solubilization of gabapentin into HII mesophases. J Phys Chem. 2010;115(5):825–35.CrossRefGoogle Scholar
  36. 36.
    Dong Z, Munson EJ, Schroeder SA, Prakash I, Grant DJW. Neotame anhydrate polymorphs II-quantitation and relative physical stability. Pharm Res-Dordr. 2002;19(9):1259–64.CrossRefGoogle Scholar
  37. 37.
    Schammé B, Couvrat N, Malpeli P, Dudognon E, Delbreilh L, Dupray V, et al. Transformation of an active pharmaceutical ingredient upon high-energy milling—a process-induced disorder in Biclotymol. Int J Pharmaceut. 2016;499(1–2):67–73.CrossRefGoogle Scholar
  38. 38.
    Calvo NL, Kaufman TS, Maggio RM. A PCA-based chemometrics-assisted ATR-FTIR approach for the classification of polymorphs of cimetidine: application to physical mixtures and tablets. J Pharmaceut Biomed. 2015;107(25):419–25.CrossRefGoogle Scholar
  39. 39.
    Volpe DA, Gupta A, Ciavarella AB, Faustino PJ, Sayeed VA, Khan MA. Comparison of the stability of split and intact gabapentin tablets. Int J Pharmaceut. 2008;350(1–2):65–9.CrossRefGoogle Scholar
  40. 40.
    Zhang J, Lv X. Study on the stability of gabapentin. Journal of Chemical Engineering of Chinese Universities. 2012 2012-10-15(05):800–5.Google Scholar
  41. 41.
    Sun H, Ren P, Fried JR. The COMPASS force field: parameterization and validation for phosphazenes. Comput Theor Polym Sci. 1998;1–2(8):229–46.CrossRefGoogle Scholar
  42. 42.
    Bunte SW. Molecular modeling of energetic materials: the parameterization and validation of nitrate esters in the COMPASS force field. J Phys Chem B. 2000;11(104):235–65.Google Scholar
  43. 43.
    Ibers JA. Gabapentin and gabapentin monohydrate. Acta Cryst. 2001;C57:641–3.Google Scholar
  44. 44.
    Tokmakoff A, Lang MJ, Jordanides XJ, Fleming GR. The intermolecular interaction mechanisms in liquid CS2 at 295 and 165 K probed with two-dimensional Raman spectroscopy. Chem Phys. 1998;233(2):231–42.CrossRefGoogle Scholar
  45. 45.
    Mogi I, Kamiko M. Striking effects of magnetic field on the growth morphology of electrochemical deposits. J Cryst Growth. 1996;166(1–4):276–80.CrossRefGoogle Scholar
  46. 46.
    Braga D, Grepioni F, Maini L, Rubini K, Polito M, Brescello R, et al. Polymorphic gabapentin: thermal behaviour, reactivity and interconversion of forms in solution and solid-state. New J Chem. 2008;10:1645–808.Google Scholar
  47. 47.
    Ehtezazi T, Govender T, Stolnik S. Hydrogen bonding and electrostatic interaction contributions to the interaction of a cationic drug with polyaspartic acid. Pharm Res-Dordr. 2000;17(7):871–8.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  1. 1.National Pharmaceutical Engineering Research CenterChina State Institute of Pharmaceutical IndustryShanghaiChina
  2. 2.School of Medical Instrument and Food EngineeringUniversity of Shanghai for Science and TechnologyShanghaiChina
  3. 3.School of PharmacyFudan UniversityShanghaiChina
  4. 4.Department of Nuclear MedicineShanghai Tenth People’s HospitalShanghaiChina

Personalised recommendations